Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193777 | 0.79 | L3MBTL1 (0.64) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL25359614 | 0.79 | L3MBTL1 (0.64) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL25358145 | 0.79 | L3MBTL1 (0.68) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL9743896 | 0.75 | L3MBTL1 (0.73) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL12344537 | 0.75 | L3MBTL1 (1.00) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL9744305 | 0.75 | L3MBTL1 (0.68) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL7365330 | 0.73 | L3MBTL1 (0.55) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL19808153 | 0.72 | L3MBTL1 (0.63) | L3MBTL1EPHX2HSD11B1HSD17B10ALDH1A1 | |
| SCHEMBL19808152 | 0.71 | L3MBTL1 (0.57) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 | |
| SCHEMBL12968364 | 0.71 | L3MBTL1 (0.72) | L3MBTL1EPHX2NPSR1HSD11B1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | L3MBTL1 2171/4885EPHX2 3517/4885NPSR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.